BriaCell Therapeutics to Acquire Lexo, Inc. for $10M
Ticker: BCTXZ · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1610820
Sentiment: bullish
Topics: acquisition, oncology, pipeline-expansion
Related Tickers: BCTX
TL;DR
BriaCell buying Lexo for $10M to boost cancer drug pipeline.
AI Summary
BriaCell Therapeutics Corp. announced on April 1, 2024, that it has entered into a definitive agreement to acquire all of the outstanding shares of Lexo, Inc. for a purchase price of $10 million. The acquisition is expected to close in the second quarter of 2024 and is anticipated to significantly expand BriaCell's oncology pipeline.
Why It Matters
This acquisition could bolster BriaCell's drug development capabilities in oncology, potentially leading to new treatment options for cancer patients.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and the possibility that the acquired assets may not perform as expected.
Key Numbers
- $10.0M — Acquisition Price (BriaCell is acquiring Lexo, Inc. for this amount.)
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Acquiring company
- Lexo, Inc. (company) — Acquired company
- $10 million (dollar_amount) — Purchase price for Lexo, Inc.
- April 1, 2024 (date) — Date of definitive agreement
- second quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary strategic rationale behind BriaCell's acquisition of Lexo, Inc.?
The acquisition is expected to significantly expand BriaCell's oncology pipeline.
What is the total purchase price for Lexo, Inc.?
The purchase price is $10 million.
When is the acquisition of Lexo, Inc. expected to be completed?
The acquisition is expected to close in the second quarter of 2024.
What is the name of the company BriaCell Therapeutics Corp. is acquiring?
BriaCell Therapeutics Corp. is acquiring Lexo, Inc.
What is the filing date of this Form 8-K?
The filing date is April 2, 2024, reporting events as of April 1, 2024.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-04-02 16:05:43
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 191KB
- ex99-2.htm (EX-99.2) — 309KB
- ex99-2_001.jpg (GRAPHIC) — 14KB
- ex99-2_002.jpg (GRAPHIC) — 6KB
- ex99-2_003.jpg (GRAPHIC) — 12KB
- ex99-2_004.jpg (GRAPHIC) — 14KB
- ex99-2_005.jpg (GRAPHIC) — 20KB
- ex99-2_006.jpg (GRAPHIC) — 15KB
- ex99-2_007.jpg (GRAPHIC) — 13KB
- ex99-2_008.jpg (GRAPHIC) — 16KB
- 0001493152-24-012774.txt ( ) — 986KB
- bctx-20240401.xsd (EX-101.SCH) — 4KB
- bctx-20240401_def.xml (EX-101.DEF) — 26KB
- bctx-20240401_lab.xml (EX-101.LAB) — 36KB
- bctx-20240401_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams April 2, 2024 William V. Williams President and Chief Executive Officer